Literature DB >> 26620046

[Levosimendan for septic shock with takotsubo cardiomyopathy].

C-N Schlürmann1, J Reinöhl2, J Kalbhenn3.   

Abstract

As a stress-induced disease, takotsubo cardiomyopathy can also occur in septic syndromes; however, the hemodynamic management is fundamentally different from the treatment approaches for classical septic cardiomyopathy, as beta mimetics can increase the heart failure symptoms in takotsubo cardiomyopathy. This article reports the case of an 82-year-old female patient who presented with acute abdomen due to adhesion ileus and takotsubo cardiomyopathy, developed severe septic shock with peritonitis and could be successfully hemodynamically stabilized with levosimendan.

Entities:  

Keywords:  Adrenaline; Hemodynamics; Inotropic agents; Septic shock; Stress

Mesh:

Substances:

Year:  2016        PMID: 26620046     DOI: 10.1007/s00101-015-0114-7

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  15 in total

1.  Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.

Authors:  Andrea Morelli; Stefano De Castro; Jean-Louis Teboul; Mervyn Singer; Monica Rocco; Giorgio Conti; Leonardo De Luca; Emanuele Di Angelantonio; Alessandra Orecchioni; Natesa G Pandian; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

Review 2.  The ins and outs of adrenergic signaling.

Authors:  Martin J Lohse
Journal:  J Mol Med (Berl)       Date:  2015-07-23       Impact factor: 4.599

3.  Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series.

Authors:  Francesco Santoro; Riccardo Ieva; Armando Ferraretti; Vincenzo Ienco; Giuseppe Carpagnano; Michele Lodispoto; Luigi Di Biase; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Cardiovasc Ther       Date:  2013-12       Impact factor: 3.023

Review 4.  [Tako-Tsubo cardiomyopathy].

Authors:  J Roggenbach; R Roggenbach; P Ehlermann
Journal:  Anaesthesist       Date:  2010-07       Impact factor: 1.041

5.  Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli.

Authors:  H Mori; S Ishikawa; S Kojima; J Hayashi; Y Watanabe; J I Hoffman; H Okino
Journal:  Cardiovasc Res       Date:  1993-02       Impact factor: 10.787

6.  [Historical and current pathophysiological concepts of stress (Tako-Tsubo) cardiomyopathy].

Authors:  S Szardien; H Möllmann; A Elsässer; C W Hamm; H M Nef
Journal:  Herz       Date:  2010-06       Impact factor: 1.443

Review 7.  Mechanisms of stress (Takotsubo) cardiomyopathy.

Authors:  Holger M Nef; Helge Möllmann; Yoshihiro J Akashi; Christian W Hamm
Journal:  Nat Rev Cardiol       Date:  2010-03-02       Impact factor: 32.419

Review 8.  Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.

Authors:  A Pathak; M Lebrin; A Vaccaro; J M Senard; F Despas
Journal:  J Clin Pharm Ther       Date:  2013-04-18       Impact factor: 2.512

9.  High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy.

Authors:  Alexander R Lyon; Sian E Harding; Helen Paur; Peter T Wright; Markus B Sikkel; Matthew H Tranter; Catherine Mansfield; Peter O'Gara; Daniel J Stuckey; Viacheslav O Nikolaev; Ivan Diakonov; Laura Pannell; Haibin Gong; Hong Sun; Nicholas S Peters; Mario Petrou; Zhaolun Zheng; Julia Gorelik
Journal:  Circulation       Date:  2012-06-25       Impact factor: 29.690

10.  An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.

Authors:  Robert M L'E Orme; Gavin D Perkins; Daniel F McAuley; Kathleen D Liu; Alexina J Mason; Andrea Morelli; Mervyn Singer; Deborah Ashby; Anthony C Gordon
Journal:  Trials       Date:  2014-06-02       Impact factor: 2.279

View more
  1 in total

1.  [Levosimendan-no effect on multiorgan failure in septic shock].

Authors:  U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-20       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.